Skip to main content

Free Content COPD management. Part I. Strategies for managing the burden of established COPD [State of the Art Series. Chronic obstructive pulmonary disease in high- and low-income countries. Edited by G. Marks and M. Chan-Yeung. Number 5 in the series]

Effective management of chronic obstructive pulmonary disease (COPD) is dependent on an accurate diagnosis and assessment of severity. COPD is a clinical diagnosis, based on a history of exposure to known risk factors and the presence of airway obstruction that is not fully reversible. Maximal therapy and support for smoking cessation should be offered to all patients. Symptoms may only develop when a significant loss of lung function has occurred, and the diagnosis is frequently made late in the course of the disease. Earlier diagnosis is dependent on a high index of suspicion, particularly in current and ex-smokers or those exposed to occupational dusts and indoor pollution, and accurate performance and interpretation of spirometry. Established COPD associated with symptoms should initially be treated with bronchodilators as needed, but long-acting bronchodilators should be used when symptoms persist and inhaled corticosteroids added for moderate to severe airflow limitation, particularly when associated with exacerbations. Combination long-acting bronchodilators and inhaled corticosteroids reduce the exacerbation rate and improve the quality of life and symptoms, but they have not been shown to improve survival. Exacerbations are associated with worsening health status and can be managed effectively at home. When symptoms worsen despite optimal treatment for exacerbations, hospital admission is necessary. Non-invasive ventilation has reduced the need for mechanical ventilation, but hospital admission and respiratory failure are associated with a significantly worse prognosis. Pulmonary rehabilitation plays an important role in improving exercise capacity at all severities of COPD, and should be widely available.

Keywords: COPD; exacerbations; management; treatment

Document Type: Invited Paper

Affiliations: Woolcock Institute of Medical Research, Camperdown, New South Wales, Australia

Publication date: 01 June 2008

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content